SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart. (2019)
Attributed to:
Investigating the renal microvasculature in polycystic kidney disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jacbts.2018.10.002
PubMed Identifier: 30847415
Publication URI: http://europepmc.org/abstract/MED/30847415
Type: Journal Article/Review
Volume: 4
Parent Publication: JACC. Basic to translational science
Issue: 1
ISSN: 2452-302X